U.S. Markets closed
  • S&P Futures

    4,272.00
    -9.00 (-0.21%)
     
  • Dow Futures

    33,651.00
    -67.00 (-0.20%)
     
  • Nasdaq Futures

    13,546.00
    -31.75 (-0.23%)
     
  • Russell 2000 Futures

    2,011.20
    -5.70 (-0.28%)
     
  • Crude Oil

    91.35
    -0.74 (-0.80%)
     
  • Gold

    1,812.00
    -3.50 (-0.19%)
     
  • Silver

    20.70
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0249
    -0.0008 (-0.0820%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2112
    -0.0027 (-0.2204%)
     
  • USD/JPY

    133.3110
    -0.1690 (-0.1266%)
     
  • BTC-USD

    24,726.33
    +179.37 (+0.73%)
     
  • CMC Crypto 200

    590.07
    +18.79 (+3.29%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,852.37
    +305.39 (+1.07%)
     

Needham Remains Bullish On UK-Based MedTech Stock Citing Upcoming Catalyst

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • LivaNova PLC (NASDAQ: LIVNcould provide an update on its RECOVER difficult-to-treat depression (DTD) trial within the next few months, representing a significant catalyst.

  • Unipolar enrollment in the trial is approaching 325-350 patients, which management has indicated is the "sweet spot" where the trial could meet its endpoint.

  • Needham believes that LIVN shares could increase by ~25-35% from ~$60 to ~$75-80 immediately after a positive disclosure and continue to increase in the following weeks.

  • But the negative outcome could immediately drag the shares by ~10-20% from ~$60 to ~$50-55.

  • LIVN expects to transition from the trial phase to the registry phase in late 2022 or early 2023, allowing a significant increase in the volume of DTD procedures since up to 5,800 patients are allowed in the registry under the RECOVER trial design.

  • The full data from the RECOVER trial will not be available until all patients reach 12 months of follow-up, likely in 2H of 2023.

  • The company expects CMS to issue an updated national coverage determination for DTD in 2H of 2024.

  • Price Action: LIVN shares are up 1.29% at $61.38 during the market session on the last check Monday.

Latest Ratings for LIVN

Date

Firm

Action

From

To

Feb 2022

UBS

Upgrades

Neutral

Buy

Feb 2022

Needham

Maintains

Buy

Dec 2021

Goldman Sachs

Initiates Coverage On

Buy

View More Analyst Ratings for LIVN

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.